Sartorius and BICO will work together on R&D projects pertaining to 3D cell printing, related technologies, and digital tools for cell line development progression.

In the APAC area, Sartorius will start acting as a distributor for BICO.

“Sartorius and BICO will work together on R&D projects pertaining to 3D cell printing, related technologies, and digital tools for cell line development progression.“

Sartorius will own just over 10% of BICO’s shares and 8.5% of voting rights as part of their overall shareholding.

Sartorius’ executive Board member and Lab Products/ Services Division Lead, Gerry Mackay, said that this will “strengthen our activities in advanced cell models and digital workflows in drug research and development.” Improving “the position of both companies in the fast-growing Asian markets with highly differentiating and relevant technologies.”

Erik Gatenholm, BICO’s Chief Executive Officer, explained that “BICO will get access to value adding, complementary technologies and products, which will enhance our current customer offering within bioprinting and lab automation. We consider the Sartorius ownership in BICO as a verification of the BICO growth strategy.”

BICO offers lab automation and life science resolutions that improve the production of novel medicines and reduce the necessity for testing on animals.

BICO’s product portfolio includes 32,000 devices in over 3,500 labs across 65 markets. The companies ultimate goal is to minimise global organ scarcity and accelerate medicine discovery.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.